Lucan · Conditions

Antithyroid drug therapy

Australian guidance: eTG Endocrinology — Hyperthyroidism + Australian Medicines Handbook (Carbimazole, Propylthiouracil monographs)

1. Definition and epidemiology

Antithyroid drug (ATD) therapy refers to the thionamide agents, carbimazole and propylthiouracil (PTU), used to suppress excess thyroid hormone synthesis in hyperthyroidism, most commonly Graves' disease. In Australia, thionamides are the default first-line treatment for Graves' disease and are also used pre-operatively and pre-radioiodine to render a thyrotoxic patient biochemically safe before a more definitive intervention. This note is the pharmacology-focused companion to the disease-level hyperthyroidism topic and assumes that background; the emphasis here is the mechanism, drug-selection logic, and safety monitoring that distinguish carbimazole from PTU, the choice between a titration and a block-and-replace regimen, adjunctive beta-blockade, how ATDs sit alongside radioiodine and surgery, and their role in thyroid storm. Minor adverse effects (rash, arthralgia, gastrointestinal upset) are reported in roughly 5 to 15% of patients started on a thionamide, per AMH and eTG Endocrinology, but the two effects that drive the safety counselling given at every initiation are agranulocytosis and hepatotoxicity, both idiosyncratic and both potentially fatal if unrecognised.

2. Pathophysiology

Thyroid hormone synthesis within the follicular cell proceeds through iodide trapping via the sodium-iodide symporter, oxidation of iodide by thyroid peroxidase (TPO), organification (iodination of tyrosine residues on thyroglobulin to form monoiodotyrosine and diiodotyrosine), and TPO-mediated coupling of these iodotyrosines to form T3 and T4, which are then stored as colloid within the follicular lumen until proteolytic release (Robbins Ch 24). Carbimazole is a prodrug that is rapidly and almost completely converted in vivo to its active metabolite, methimazole; both methimazole and PTU are thionamides that inhibit TPO, blocking organification and coupling and therefore new hormone synthesis. Critically, thionamides do not block the release of hormone already stored as colloid, which is why clinical improvement lags drug initiation by several weeks (existing stores must be depleted) and why a thionamide alone acts too slowly to be the sole agent in an acute crisis such as thyroid storm.

PTU has one further mechanism that methimazole (and therefore carbimazole) lacks: at higher doses it inhibits type 1 deiodinase in peripheral tissues (liver, kidney, skeletal muscle), reducing conversion of the less active T4 to the more biologically active T3. This peripheral action, together with PTU's lower rate of placental transfer relative to carbimazole, is the pharmacological basis for its preferred use in the first trimester of pregnancy and in thyroid storm, the two clinical settings where PTU is favoured over carbimazole despite carbimazole otherwise being the default agent.

3. Clinical presentation and diagnostic criteria

The clinical trigger for starting a thionamide is the standard biochemical picture of overt hyperthyroidism (suppressed TSH with elevated free T4, free T3, or both), most often in confirmed or strongly suspected Graves' disease. Two decision points recur through ATD prescribing and are the core exam-relevant reasoning of this topic.

First, agent choice: carbimazole is used for essentially all adult non-pregnant patients and outside thyroid storm, while PTU is reserved for the first trimester of pregnancy (teratogenicity avoidance) and thyroid storm (added peripheral T4-to-T3 blockade); many Australian protocols switch a woman from PTU back to carbimazole once the first trimester has passed, trading the small residual teratogenic risk for a lower cumulative hepatotoxicity exposure from prolonged PTU use.

Second, regimen choice: a titration (dose-titration) approach starts at a higher induction dose and steps the dose down as the patient becomes biochemically euthyroid, whereas a block-and-replace approach fixes the thionamide at a higher blocking dose throughout and adds levothyroxine once euthyroid to prevent iatrogenic hypothyroidism. Neither regimen is diagnostic; both are chosen once the diagnosis and severity of hyperthyroidism are already established.

4. Investigations and AU-specific details

Before starting either thionamide, a baseline full blood count and liver function tests are obtained, both to have a pre-treatment reference point and because pre-existing neutropenia or hepatic impairment changes the risk calculus. Free T4 (and free T3 where relevant) and TSH are then rechecked every four to six weeks after initiation until the patient is euthyroid, guiding dose titration in the titration regimen; TSH remains suppressed for some time even after free T4 normalises, because pituitary thyrotroph recovery lags peripheral biochemical control, so dose adjustment in the early phase is driven by free T4 rather than TSH. TSH-receptor antibody (TRAb) titre at twelve to eighteen months, consistent with eTG Endocrinology guidance, is used to inform the decision to trial stopping the thionamide: a falling or negative titre predicts a higher chance of sustained remission, whereas a persistently high titre predicts relapse and prompts earlier consideration of radioiodine or surgery. Routine scheduled full blood counts during therapy are not recommended by the Australian Medicines Handbook or eTG as a screening tool for agranulocytosis, because the onset is too abrupt to be reliably caught between visits; instead, blood testing is symptom-triggered, discussed further below.

5. Management

Management follows eTG Endocrinology guidance and is stratified by agent, regimen, and definitive-therapy timing. Carbimazole is typically started at 15 to 60 mg daily in divided doses depending on severity (mild 15–20 mg, moderate 30 mg, severe 40–45 mg up to 60 mg), then titrated down over weeks to months to a maintenance dose (usually 10 to 15 mg daily) that keeps free T4 within range, with a total course of twelve to eighteen months before a trial of cessation is considered. Block-and-replace (fixed-dose carbimazole plus levothyroxine) is a reasonable alternative in patients whose biochemistry fluctuates on titration or who find frequent dose changes difficult to manage, though it exposes the patient to a higher cumulative carbimazole dose without a proven remission advantage over titration, and is generally avoided in pregnancy for that reason; titration remains the more commonly used first-line approach in Australian practice.

Propranolol (20 to 40 mg three to four times daily) or atenolol (50 to 100 mg once daily) is added for rapid symptomatic control of tremor, palpitations, anxiety, and heat intolerance while the thionamide's effect on hormone synthesis takes weeks to become apparent; propranolol carries the incidental advantage of some peripheral T4-to-T3 blockade at higher doses, mechanistically analogous to PTU, though this is a minor contributor compared with its primary beta-blocking action.

Where a thionamide alone is insufficient or intolerance/adverse effects intervene, radioiodine (iodine-131) and total thyroidectomy are the two definitive alternatives; both require the patient to be rendered euthyroid on a thionamide beforehand wherever possible, since radiation-induced or surgical release of stored hormone from an actively thyrotoxic gland can itself precipitate thyroid storm. Radioiodine is favoured for its non-surgical convenience and lower procedural risk but is contraindicated in pregnancy and breastfeeding, in active moderate-to-severe Graves' orbitopathy (which it can worsen), and in suspected malignancy; nearly all patients become hypothyroid over the following months to years and need lifelong levothyroxine, an expected outcome of adequate treatment rather than a complication. Surgery (total thyroidectomy, preferred over subtotal to minimise recurrence) suits a large compressive goitre, suspected or confirmed malignancy, active orbitopathy where radioiodine is unsuitable, or patient preference for a rapid, non-radioactive cure; potassium iodide (Lugol's solution) is added for five to ten days pre-operatively to reduce gland vascularity, given only after thionamide loading so that the iodine substrate does not fuel further synthesis in an incompletely blocked gland.

Thyroid storm is managed as a medical emergency, in brief: high-dose PTU is the preferred first thionamide because its added peripheral deiodinase blockade lowers active T3 faster than carbimazole; potassium iodide is given at least one hour after the PTU load to exploit the Wolff-Chaikoff effect and acutely suppress hormone release without adding synthetic substrate; high-dose propranolol controls the adrenergic and cardiovascular manifestations; hydrocortisone or dexamethasone is given both for peripheral T4-to-T3 blockade and to cover possible relative adrenal insufficiency; and aggressive supportive care (active cooling, fluid resuscitation, and treatment of the precipitant, commonly infection, surgery, trauma, or abrupt ATD cessation) is delivered in a monitored or intensive care setting, reflecting the substantial mortality that persists even with prompt treatment.

6. Pharmacology and AU PBS notes

Carbimazole (AU brand Neo-Mercazole, 5 mg tablets only — there is no 20 mg strength marketed in Australia, so higher induction doses are taken as multiple 5 mg tablets) is PBS-listed for hyperthyroidism without authority requirement and is the default thionamide in Australian practice. PTU (50 mg tablets, PBS-listed) is dosed at an initial 200 to 400 mg daily in divided doses (eight-hourly), up to 600–1200 mg daily in severe disease, then reduced to a maintenance dose of approximately 50 to 150 mg daily once the patient is euthyroid; PTU is reserved for first-trimester pregnancy and thyroid storm because of its higher hepatotoxicity risk with prolonged use.

Agranulocytosis occurs with both agents at a rate of roughly 0.2 to 0.5%, is idiosyncratic and largely unpredictable rather than reliably dose-dependent, and characteristically develops abruptly, most often within the first three months of therapy though it can occur at any point. Every patient started on a thionamide is given the sore-throat rule at initiation: stop the drug immediately and seek an urgent full blood count with differential at the first sign of fever, sore throat, mouth ulcers, or other features suggesting infection, because symptom-triggered testing, not scheduled surveillance blood counts, is the safety net that actually catches an event with this abrupt an onset. If agranulocytosis is confirmed, the thionamide is stopped permanently; because carbimazole (via methimazole) and PTU show significant cross-reactivity, switching to the other agent is generally avoided, and definitive therapy with radioiodine or surgery is pursued instead.

Hepatotoxicity differs in pattern and severity between the two drugs: carbimazole typically causes a cholestatic, usually mild and reversible pattern of liver injury, whereas PTU carries a well-recognised risk of severe hepatocellular injury, including rare cases of fulminant hepatic failure, which is the principal reason PTU is not used as a general first-line agent and is largely avoided in children outside pregnancy-related indications. Patients on either drug are counselled to report jaundice, dark urine, pale stool, right upper quadrant pain, or unexplained nausea, and baseline plus symptom-triggered liver function tests are the standard monitoring approach, mirroring the symptom-triggered logic used for agranulocytosis.

7. Complications and monitoring

Beyond agranulocytosis and hepatotoxicity, thionamides carry a small risk of ANCA-associated vasculitis, reported more often with PTU than carbimazole, and a teratogenic risk specific to carbimazole in the first trimester (aplasia cutis congenita, choanal and oesophageal atresia, collectively sometimes termed carbimazole embryopathy), which is why PTU substitutes for carbimazole in early pregnancy despite PTU's own less favourable long-term hepatotoxicity profile.

Standard monitoring during ATD therapy is free T4 (and TSH once it recovers) every four to six weeks until euthyroid, then roughly every three months on a stable maintenance dose, with full blood count and liver function tests obtained urgently, not routinely, whenever red-flag symptoms arise. TRAb titre at twelve to eighteen months guides the decision to trial cessation, consistent with eTG Endocrinology; following radioiodine, TSH and free T4 are checked at six weeks, three months, and six months, then annually once hypothyroidism is established and levothyroxine replacement is stable. In pregnancy, free T4 and TSH are checked every four weeks, with the dose kept to the lowest that maintains maternal free T4 in the upper third of the trimester-specific reference range, minimising fetal exposure to placentally transferred ATD while avoiding fetal hypothyroidism from over-treatment.

Written for Australian practice and grounded in the guidance named above. Study material only — not medical advice. Always check against current guidelines.